Item 8.01 Other Events.
Press Release
On January 3, 2022, Genprex, Inc. (the "Company") issued a press release
announcing that the U.S. Food and Drug Administration had granted Fast Track
Designation for the Company's lead drug candidate, REQORSA™ Immunogene Therapy,
in combination with Merck & Co's Keytruda® in patients with
histologically-confirmed unresectable stage III or IV non-small cell lung cancer
whose disease progressed after treatment with Keytruda. The full text of the
press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Corporate Presentation
The investor presentation about Genprex, Inc. (the "Company") that is furnished
as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by
reference may be presented at meetings with investors, analysts, and others, in
whole or in part and possibly with modifications, from time to time on or after
January 3, 2022. A copy of the investor presentation slides, substantially in
the form expected to be used in such presentations and meetings, will be
available on the Company's website, www.genprex.com.
The information contained in the investor presentation is summary information
that is intended to be considered in the context of the Company's Securities and
Exchange Commission ("SEC") filings and other public announcements that the
Company may make, by press release or otherwise, from time to time. The Company
undertakes no duty or obligation to publicly update or revise the information
contained in this Current Report on Form 8-K, although it may do so from time to
time as its management believes is warranted. Any such updates may be made
through the filing of other reports or documents with the SEC, through press
releases or through other public disclosure.
The information presented in Item 8.01 of this Current Report on Form 8-K under
"Corporate Presentation" and Exhibit 99.2 shall not be deemed to be "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), or otherwise subject to the liabilities of that section. The
information in this Item 8.01 under "Corporate Presentation" and Exhibit 99.2 of
this Current Report on Form 8-K shall not be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date of this Current Report on Form 8-K,
regardless of any general incorporation language in any such filing.
Item 9.01: Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
99.1 Press Release dated January 3, 2022, issued by Genprex, Inc.
99.2 Investor Presentation
104 Inline XBRL for the cover page of this Current Report on Form 8-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses